建溢集團(00638.HK)著手改裝車間以生產口罩及防護衣
建溢集團(00638.HK)公布,目前集團旗下位於廣東省的兩間工廠已經獲得相關批准恢復生產,初步報到上班的員工平均約有總人數的三分之一,預期集團所有工廠(包括位於深圳的電器及電子產品分類的主要工廠,以及位於貴州省電機業務分類的另一家工廠)將於適當時候逐步恢復生產。
同時,集團正著手在中國生產醫療防護口罩,在此初步階段將利用現有生產資源、改造現有的無塵車間生產設施、購買口罩組裝生產設備以及與地方政府協作以盡可能加快展開生產前需要通過的驗證程序。視乎相關生產線的交付情況,集團預期於不久後達到每日生產約26.4萬至72萬個口罩的產能。集團亦可能在下一階段考慮生產醫療防護衣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.